Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 574 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Protease + Protein Clear all
Completed Phase 3 Interventional

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01776606
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Endoscopic Gastric Reduction for Weight Management

NCT01682733
View directory record Official record
Conditions
Obesity
Interventions
Botulinum toxin, Overstitch Endoscopic Suturing System
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 13, 2026, 6:45 PM EDT
Not listed Not applicable Interventional

Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion

NCT00103766
View directory record Official record
Conditions
Empyema, Pleural Effusion
Interventions
Alteplase
Drug
Lead sponsor
O'Brien, Jeana D., MD, FACP, FCCP
Individual
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2006 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

NCT00301366
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
alpha-1 proteinase inhibitor (human)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks

NCT00604695
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Tenecteplase, Sterile Saline
Drug
Lead sponsor
C. Michael Gibson, MS, MD
Other
Eligibility
18 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Gainesville, Florida • Atlanta, Georgia • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 13, 2026, 6:45 PM EDT
Withdrawn Phase 3 Interventional

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

NCT04675086
View directory record Official record
Conditions
Covid19, Pneumonia, Viral
Interventions
alpha1-proteinase inhibitor, Antiviral Agents
Drug
Lead sponsor
Blessing Corporate Services, Inc
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Hannibal, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

NCT01358695
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
ANT-1207, Botulinum Toxin Type A
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami Beach, Florida • West Palm Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2013 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

NCT02565732
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum toxin type A, Placebo comparator
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions
Recombinant tissue plasminogen activator (rt-PA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years to 75 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
56
States / cities
Glendale, Arizona • Orange, California • Stanford, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 13, 2026, 6:45 PM EDT
Completed No phase listed Observational Results available

A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

NCT01749410
View directory record Official record
Conditions
Chronic Migraine, Headaches
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Brow Enhancement Study

NCT01308593
View directory record Official record
Conditions
Brow Ptosis
Interventions
Juvederm XC, Botox
Device · Drug
Lead sponsor
Skin Care and Laser Physicians of Beverly Hills
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 13, 2026, 6:45 PM EDT
Not listed No phase listed Observational

An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

NCT06154070
View directory record Official record
Conditions
Migraine Disorders
Interventions
DaxibotulinumtoxinA
Drug
Lead sponsor
Ki Health Partners. LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

NCT02230956
View directory record Official record
Conditions
Osteoarthritis
Interventions
onabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 13, 2026, 6:45 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969
View directory record Official record
Conditions
Oxidative Stress, Endothelial Dysfunction
Interventions
valsartan (ARB), ramipril (ACE inhibitor), Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Facial Aesthetic Treatment in Millennials

NCT04755595
View directory record Official record
Conditions
Dermatological Non-Disease
Interventions
Botox Cosmetic Injectable Product, Juvéderm Voluma XC, Juvéderm Volbella XC
Drug · Device
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
24 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort

NCT00628472
View directory record Official record
Conditions
Pain
Interventions
botulinum type a
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 3 Interventional

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

NCT00028301
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Lopinavir/Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Sep 13, 2026, 6:45 PM EDT
Terminated Phase 3 Interventional Results available

Botox for Non-surgical Lateral Release in Patellofemoral Pain

NCT00496964
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
Botulinum toxin A + exercise, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

NCT02498769
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Joseph Mathew, M.D.
Other
Eligibility
50 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 13, 2026, 6:45 PM EDT
Terminated Phase 2 Interventional Results available

Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

NCT00252239
View directory record Official record
Conditions
Stroke
Interventions
tenecteplase, tissue plasminogen activator, tPA
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
San Diego, California • Englewood, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 2 Interventional

A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

NCT00385502
View directory record Official record
Conditions
Onychomycosis
Interventions
EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 13, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Lower Limb Spasticity Study

NCT01249404
View directory record Official record
Conditions
Leg Spasticity
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
17
States / cities
Scottsdale, Arizona • Downey, California • Oxnard, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 13, 2026, 6:45 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00439140
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 13, 2026, 6:45 PM EDT
Not listed Not applicable Interventional

The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder

NCT02315950
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botulinum toxin and cineMRI-UDS
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 13, 2026, 6:45 PM EDT